CVS Health Corporation
NYSECVS short interest climbed 20.9% over the past week to 1.52% of free float, though shares fell 1.3% Wednesday as stock declined 1.6%. Cost to borrow remains minimal at 0.46%, with near-zero utilization at 0.46%.
CVS Health enters September on the front foot — up 5% on the week and 3.9% on Tuesday alone — yet options positioning tells a more guarded story, and the gap between price recovery and a still-challenged earnings…
CVS Health is finding its footing at $94.91 — up 1.5% on the week — after the brutal August 5 earnings drop, with the Street continuing to ratchet up price targets even as the stock trades nearly 22% below…
Snapshot as of 20 Sept 2026
CVS Health is trading at $93.50 after a brutal week — down 10.5% — yet the short community is actively covering and the Street is quietly raising targets, creating a sharp divergence between where the stock went and…
CVS Health reported its Q2 results on August 5 and the immediate verdict from the market is a 4.5% weekly loss, even as the analyst community keeps its targets well above where the stock now trades. The price action…
CVS Health heads into its August 5 earnings release with the strongest analyst tailwind it has seen in months, trading at $104.43 against a consensus target of $113.50. The analyst setup is unusually constructive.…
CVS Health has done something awkward this week — it outran the Street's targets. Since the last note published on July 8, two more firms lifted their price targets. Truist Securities raised to $118 on July 14. Wells…
CVS Health heads into its August 5 earnings with the Street in unusually unanimous agreement — and the stock trading within a few dollars of where the bulls want it. The analyst upgrade cycle has been relentless. Every…
CVS Health has given back a little ground this week, but the narrative from the Street continues to move in one direction: higher. The stock dipped 1.9% on Tuesday to close at $94.18, trimming its weekly gain to -1.0%.…
CVS Health has just delivered its biggest weekly gain in years — up 18% — and the analyst community has responded with a rare, almost unanimous round of target-price upgrades. The week's most compelling story is not…
CVS Health enters its May 14 earnings report carried by a wave of analyst upgrades that has reset expectations sharply higher heading into the print. The most striking pre-earnings signal is from the Street, where at…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CVS — free to start on ORTEX.
Sign up for free →Open CVS on ORTEX